BLOOMFIELD HILLS, Mich. / Jul 08, 2024 / Business Wire / ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global animal health company. This new study aims to further... Read More

BLOOMFIELD HILLS, Mich. / Oct 30, 2023 / Business Wire / Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”) , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day study to further validate the efficacy of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO... Read More

BLOOMFIELD HILLS, Mich. / Oct 26, 2023 / Business Wire / Zivo Bioscience, Inc. (NASDAQ: ZIVO) , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that the Board of Directors of the Company approved a 1-for-6 reverse stock split (the “Reverse Stock Split”) of its shares of common stock, par value $0.001... Read More

BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”) , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that management will deliver a company presentation and will hold investor meetings at the 8 th Annual Dawson James Small Cap Growth Conference... Read More

All test groups demonstrated statistically significant benefit in broiler health under simulated commercial conditions BLOOMFIELD HILLS, Mich. / Sep 19, 2023 / Business Wire / Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”) , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive results from a... Read More

Signs manufacturing agreement to grow and process algal biomass, enters into distribution agreement for branded DTC sales of Zivolife TM BLOOMFIELD HILLS, Mich. / Jul 26, 2023 / Business Wire / Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces... Read More

BLOOMFIELD HILLS, Mich. / Jun 30, 2023 / Business Wire / Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 1,498,130 shares of common stock (or pre-funded... Read More

BLOOMFIELD HILLS, Mich. / May 30, 2023 / Business Wire / Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced it has received an updated dossier from an independent scientific review panel reconfirming the Company’s “Generally Recognized As Safe” (GRAS)... Read More

BLOOMFIELD HILLS, Mich. / Apr 05, 2023 / Business Wire / Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”) , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced a $1 million unsecured six-month loan from its Chairman, Chief Executive Officer, and President, John Payne. The loan carries 10% simple... Read More

BLOOMFIELD HILLS, Mich. / Feb 10, 2023 / Business Wire / Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”) , a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis... Read More